AbbVie Submits Supplemental New Drug Application to US FDA for cariprazine (VRAYLAR®) for the Adjunctive Treatment of Major Depressive Disorder - PRNewswire

Submitted by Anonymous (not verified) on Tue, 02/22/2022 - 13:15

AbbVie Submits Supplemental New Drug Application to US FDA for cariprazine (VRAYLAR®) for the Adjunctive Treatment of Major Depressive Disorder PRNewswire

Log in to post comments